Hepatocellular Carcinoma (HCC)

PD-1/IL-2 Bispecific Antibody as Neoadjuvant Therapy for Early Recurrent Hepatocellular Carcinoma After Curative Hepatectomy

Lenalidomide Plus Targeted Therapy and Immunotherapy for Refractory HCC

mSEPT9 Biomarker for Predicting Hepatocellular Carcinoma Occurrence in Patients With Cirrhosis

Construction and Clinical Validation of a Predictive Model for Postoperative Adjuvant Therapy in Hepatocellular Carcinoma Based on Whole-Slide Digital Pathological Images and Deep Learning

HAIC Plus Lenva and PD-1 for Advanced HCC With Macrovascular or Biliary Invasion

Registry of Minimally Invasive Cancer Treatment Using Spectral Angio-CT Image Guidance

A Phase 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid Tumors

Hepatocellular Carcinoma Study Comparing Vaccinia Virus Based Immunotherapy Plus Sorafenib vs Sorafenib Alone

Project for Multi-Omics-Based Early Detection of Hepatocellular Carcinoma (PROMETHEA Study)

Liver Transplant for Hepatocellular Carcinoma

A Phase 1 Study of the Safety and Tolerability of CTX-10726

Liver Cancer Registry Platform

Improving the Use of Immunotherapy to Treat Liver Cancer

Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study

A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)

A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies

Conversion Therapy With FOLFOX-HAIC Plus Lenvatinib And Tislelizumab For Hepatocellular Carcinoma With Vp3 Portal Vein Tumor Thrombus

Lenvatinib or Regorafenib for Advanced Hepatocellular Carcinoma After Immunotherapy (REVIVE)

Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors

Fostrox Plus Lenvatinib vs Lenvatinib in Advanced Hepatocellular Carcinoma After First-line Immunotherapy